Hormonal
Modulating gut microbiota using probiotics, prebiotics, antibiotics, or fecal microbiota transplantation improves glucose metabolism and insulin resistance in type 2 diabetes.
If you have type 2 diabetes, your gut bacteria play a key role in how your body handles sugar and insulin. You can positively influence these bacteria through specific probiotics and prebiotics (like those found in certain fermented drinks or fibers), which may help lower fasting blood sugar and improve insulin sensitivity. While not a cure, this is a valid therapeutic strategy alongside standard care.
Modulating gut microbiota with the use of probiotics, prebiotics, antibiotics, and fecal microbiota transplantation may have benefits for improvement in glucose metabolism and insulin resistance in the host.
Why this rating
The paper is a review summarizing various animal and human studies, including conflicting results in microbiota composition, but affirming therapeutic potential.
Source
Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective
Jun-Ling Han et al. · World Journal of Gastroenterology · 2014
DOI 10.3748/wjg.v20.i47.17737
More from this paper
- Fecal microbiota transplantation (FMT) from lean donors improves peripheral and hepatic insulin sensitivity in patients with metabolic syndrome.Moderate
- Antibiotic treatment (specifically norfloxacin and ampicillin) improves fasting blood glucose and oral glucose tolerance in obese, insulin-resistant mice by reducing plasma LPS levels and intestinal inflammation.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →